�BioCurex Inc. has announced that it has filed a newfangled patent application to protect certain
methods of purifying and detecting RECAF in bodily fluids. The patent application
too includes what the party believes - based on available data - to be
new methods for tumor imaging and therapy based on RECAF.
The patent applications programme has been filed as a provisionary patent application. This
means that the patent application remains undisclosed for up to 18 months at the
owner's discretion, so providing one more year of protection, and, assumptive the
patent application is granted, thus providing farther RECAF applied science
protection for another 21 years.
This patent application contains critical methods necessary for manufacturing
RECAF tests as intimately as for the generation of synthetic products to be secondhand to
target RECAF in vivo (inside the body). These products buns be manufactured at
blue cost, in highly pure form and without the need to use biological systems;
thence eliminating the possibility of carrying infective diseases to the
recipients.
As a result of the trade protection provided by this young patent lotion, the
company has confiscate its former patent coating in Japan, where differences
in patent law as compared to the USA and the EU, make resulted in unanticipated
resistance to approval. BioCurex holds granted patents in the USA, the European
Union, Russia, Australia, Norway and China at this time.
The raw application volition soon be extended through the Patent Cooperation Treaty
to the most populated and developed countries with highest market potential, as
we own done antecedently.
Dr. Moro, BioCurex's CEO stated: 'This new patent application is the solution of
various years of intense work and it reflects the value added to our company
resulting from that investment in time and money. We - and our licensees - make
been exploitation technology contained in our issued patents for some time now, in our
daily ferment. There ar other improvements that will be the subject of new patent
applications to be filed in the near future. This strategy is intended to stake
the RECAF technology with a figure of patent claims in a direction that will prevent
others from circumventing our patents as advantageously as extending the tribute period
of our technology. '
The additional auspices, offered by the claims related to blood tests in this
new patent application, is extended to our electric current licensees. This will extend
the term of our licensing agreements and consequently enhance our royalties.
However, there are also other claims related to different fields and applications
non encompassed in our stream agreements and they can be freely licensed to new
recognised licensees.
About BioCurex
BioCurex, Inc. is a biotechnology company that is developing products based on
patented/proprietary engineering in the areas of cancer diagnosis, imaging and
therapy. The technology identifies a cancer marker known as RECAFtm, which is
found on malignant cells from a variety of cancer types but is absent in most
normal or benign cells.
BioCurex has sign-language licensing agreements for its cancer detecting blood tests
with Abbott Laboratories and with Inverness Medical Innovations (for farther
information on these agreements click here.
The crab marker RECAFTM has emerged as a potential biomarker that may be useful
in the development of new cancer the Crab diagnostics tests. Preliminary studies from the
investigators at BioCurex have reported a high grade of clinical sensitivity and
specificity for RECAF in many of the most common cancers, including prostate,
breast, colorectal, lung and others.
The Company has not authorised the outlet of this information in any form that
contravenes the Communication Act and will non be responsible for unsolicited
massive dispersion of this material by e-mail or facsimile by unauthorized parties.
Statements in this press release, which are not historical facts, are
'forward-looking statements'' within the meaning given to that term in the
Private Securities Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created thereby. Since
these statements involve risks and uncertainties and are subject to change at
whatsoever time, the Company's actual results could differ materially from expected
results.
Biocurex
More info
